These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32401745)

  • 1. Alcohol-free Extemporaneous Formulations of Furosemide Are Chemically and Physically Stable in Ora-Blend Products for 30 Days.
    Svirskis D; Jaffer J; Agarwal P; Khan A; Kaur J; Cheng A; Hanning S
    Int J Pharm Compd; 2020; 24(3):246-251. PubMed ID: 32401745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding.
    Zhao F; Dave VS; Mar MZ; Perri JR
    Int J Pharm Compd; 2018; 22(5):433-439. PubMed ID: 30384342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of an extemporaneous alcohol-free melatonin suspension.
    Johnson CE; Cober MP; Thome T; Rouse E
    Am J Health Syst Pharm; 2011 Mar; 68(5):420-3. PubMed ID: 21330684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability study of oral pediatric idebenone suspensions.
    Schlatter J; Bourguignon E; Majoul E; Kabiche S; Balde IB; Cisternino S; Fontan JE
    Pharm Dev Technol; 2017 Mar; 22(2):296-299. PubMed ID: 27583702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of an extemporaneously prepared alcohol-free phenobarbital suspension.
    Cober MP; Johnson CE
    Am J Health Syst Pharm; 2007 Mar; 64(6):644-6. PubMed ID: 17353574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of extemporaneously prepared cinacalcet oral suspensions.
    Thomson K; Hutchinson DJ; Chablani L
    Am J Health Syst Pharm; 2018 May; 75(9):e236-e240. PubMed ID: 29691267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical Stability of Compounded Amlodipine Besylate Suspensions in PCCA Base, SuspendIt.
    Graves RA; Mandal TK; Bostanian LA; Nguyen AT; Swopes D; Morris TC; Pramar YV
    Int J Pharm Compd; 2019; 23(6):519-527. PubMed ID: 31751949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of cilazapril in pediatric oral suspensions prepared from commercially available tablet dosage forms.
    Stanisz BJ; Paszun SK; Zalewska A
    Acta Pol Pharm; 2014; 71(4):661-6. PubMed ID: 25272892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of extemporaneously prepared rufinamide oral suspensions.
    Hutchinson DJ; Liou Y; Best R; Zhao F
    Ann Pharmacother; 2010 Mar; 44(3):462-5. PubMed ID: 20150505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children.
    Pramann LA; Davidow LW; van Haandel L; Funk RS
    Int J Pharm Compd; 2016; 20(3):257-261. PubMed ID: 28333668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of extemporaneously prepared oxandrolone oral suspensions.
    Johnson CE; Cober MP; Hawkins KA; Julian JD
    Am J Health Syst Pharm; 2011 Mar; 68(6):519-21. PubMed ID: 21378300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality evaluation of extemporaneous delayed-release liquid formulations of lansoprazole.
    Melkoumov A; Soukrati A; Elkin I; Forest JM; Hildgen P; Leclair G
    Am J Health Syst Pharm; 2011 Nov; 68(21):2069-74. PubMed ID: 22011986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions.
    Kabiche D; Balde IB; Majoul E; Kabiche S; Bourguignon E; Fontan JE; Cisternino S; Schlatter J
    Int J Pharm Compd; 2017; 21(2):160-163. PubMed ID: 28346212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The stability of quetiapine oral suspension compounded from commercially available tablets.
    Tran J; Gervase MA; Evans J; Deville R; Dong X
    PLoS One; 2021; 16(8):e0255963. PubMed ID: 34375349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions.
    Li Q; Liu Z; Kolli S; Wetz K; Griffith N; Poi MJ
    Am J Health Syst Pharm; 2016 Sep; 73(17):1331-7. PubMed ID: 27543577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of extemporaneously prepared moxifloxacin oral suspensions.
    Hutchinson DJ; Johnson CE; Klein KC
    Am J Health Syst Pharm; 2009 Apr; 66(7):665-7. PubMed ID: 19299374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physicochemical and microbiological stability studies of extemporaneous antihypertensive pediatric suspensions for hospital use.
    Mendes C; Costa AP; Oliveira PR; Tagliari MP; Silva MA
    Pharm Dev Technol; 2013; 18(4):813-20. PubMed ID: 22670721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of extemporaneously prepared glycopyrrolate oral suspensions.
    Cober MP; Johnson CE; Sudekum D; Penprase K
    Am J Health Syst Pharm; 2011 May; 68(9):843-5. PubMed ID: 21515869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of extemporaneous enalapril maleate suspensions for pediatric use prepared from commercially available tablets.
    Sosnowska K; Winnicka K; Czajkowska-Kośnik A
    Acta Pol Pharm; 2009; 66(3):321-6. PubMed ID: 19645333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules.
    Winiarski AP; Infeld MH; Tscherne R; Bachynsky M; Rucki R; Nagano-Mate K
    J Am Pharm Assoc (2003); 2007; 47(6):747-55. PubMed ID: 18032138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.